CPX-351 (vyxeos) in AML
M Alfayez, H Kantarjian, T Kadia… - Leukemia & …, 2020 - Taylor & Francis
For decades, the standard induction for patients with acute myeloid leukemia (AML) has
been the combination of cytarabine with anthracycline (7+ 3 regimen). In August 2017 the …
been the combination of cytarabine with anthracycline (7+ 3 regimen). In August 2017 the …
Maintenance therapy in AML: the past, the present and the future
Curative treatment in acute myeloid leukemia (AML) depends on successful induction
therapy to achieve a complete remission (CR), and subsequent post‐remission therapy to …
therapy to achieve a complete remission (CR), and subsequent post‐remission therapy to …
Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
T Herold, M Rothenberg-Thurley, VV Grunwald… - Leukemia, 2020 - nature.com
Abstract The revised 2017 European LeukemiaNet (ELN) recommendations for genetic risk
stratification of acute myeloid leukemia have been widely adopted, but have not yet been …
stratification of acute myeloid leukemia have been widely adopted, but have not yet been …
New targeted agents in acute myeloid leukemia: new hope on the rise
SR Bohl, L Bullinger, FG Rücker - International journal of molecular …, 2019 - mdpi.com
The therapeutic approach for acute myeloid leukemia (AML) remains challenging, since
over the last four decades a stagnation in standard cytotoxic treatment has been observed …
over the last four decades a stagnation in standard cytotoxic treatment has been observed …
IDH inhibitors in AML—promise and pitfalls
Abstract Purpose of Review Mutations in isocitrate dehydrogenase genes (IDH1 and IDH2)
are common in acute myeloid leukemia (AML), occurring in up to 30% of AML cases …
are common in acute myeloid leukemia (AML), occurring in up to 30% of AML cases …
A review of FDA-approved acute myeloid leukemia therapies beyond '7+ 3'
A Bazinet, S Assouline - Expert review of hematology, 2021 - Taylor & Francis
Introduction: The standard anthracycline and cytarabine-based chemotherapy for acute
myeloid leukemia (AML) has changed relatively little since the 1970s and produces …
myeloid leukemia (AML) has changed relatively little since the 1970s and produces …
New drugs approved for acute myeloid leukaemia in 2018
Acute myeloid leukaemia (AML) is a haematopoietic stem cell disorder, that is characterized
by the clonal expansion of myeloid blasts and suppression of normal haematopoiesis. The …
by the clonal expansion of myeloid blasts and suppression of normal haematopoiesis. The …
IDH1-mutated relapsed or refractory AML: current challenges and future prospects
JE Megías-Vericat, O Ballesta-López… - Blood and lymphatic …, 2019 - Taylor & Francis
The prognosis of patients with relapsed or refractory acute myeloid leukemia (R/R AML) is
discouraging with salvage standard approaches. Mutations of isocitrate dehydrogenase 1 …
discouraging with salvage standard approaches. Mutations of isocitrate dehydrogenase 1 …
New drugs creating new challenges in acute myeloid leukemia
IS Tiong, AH Wei - Genes, Chromosomes and Cancer, 2019 - Wiley Online Library
The therapeutic landscape is rapidly changing, with eight new drugs approved by the Food
and Drug Administration within the last 2 years, including midostaurin and gilteritinib for …
and Drug Administration within the last 2 years, including midostaurin and gilteritinib for …
The time has come for targeted therapies for AML: lights and shadows
Acute myeloid leukemia (AML) is a complex disease characterized by genetic and clinical
heterogeneity and high mortality. After 40 years during which the standard of care for …
heterogeneity and high mortality. After 40 years during which the standard of care for …